A chemical conjugate of the tick P0 peptide is efficacious against Amblyomma mixtum.

Autor: Rodríguez-Mallon A; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Encinosa Guzmán PE; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Bello Soto Y; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Rosales Perdomo K; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Montero Espinosa C; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Vargas M; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Estrada García MP; Department of Animal Biotechnology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Jazyk: angličtina
Zdroj: Transboundary and emerging diseases [Transbound Emerg Dis] 2020 Jul; Vol. 67 Suppl 2, pp. 175-177. Date of Electronic Publication: 2020 Jan 23.
DOI: 10.1111/tbed.13455
Abstrakt: After Rhipicephalus microplus, the most important tick species affecting livestock industry in Cuba belong to the Amblyomma genus. There are few reports of effective vaccine antigens for these species. Recently, vaccination and challenge trials using a peptide from the P0 acidic ribosomal protein of R. microplus ticks (pP0) as antigen have shown an efficacy around 90% against tick species from the Rhipicephalus genus. Given the high degree of sequence conservation among tick species, pP0 could be an antigen of versatile use in anti-tick vaccine formulations. In this paper, seven rabbits were immunized with a chemical conjugate of pP0 to keyhole limpet haemocyanin. Rabbits were challenged with an average of 1,900 Amblyomma mixtum larvae from a Cuban tick strain. The average number of recovered fed larvae and the viability of larvae in the moulting process were significantly lower in vaccinated animals compared with the control group. The overall vaccine efficacy of the P0 peptide antigen is 54% according to the calculated parameters.
(© 2020 Blackwell Verlag GmbH.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje